Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: A multicenter study

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 2, 2012, Pages

  Filopanti, M ^a   Olgiati, L ^b   Mantovani, G ^b   Corbetta, S ^b,c   Arosio, M ^b,d   Gasco, V ^e   De Marinis, L ^f   Martini, C ^g   Bogazzi, F ^h   Cannavo S ⁱ   Colao, A ^j   Ferone, D ^k   Arnaldi, G ^l   Pigliaru, F ^m   Peri, A ⁿ   Angeletti, G ^o   Jaffrain Rea, M L ^p   Lania, A G ^b,q   Spada, Anna ^a,b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

^d IRCCS MULTIMEDICA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h UNIVERSITY OF PISA   (Italy)

ⁱ UNIVERSITY OF MESSINA   (Italy)

^j UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^k UNIVERSITY OF GENOA   (Italy)

^l UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^m DEPARTMENT OF RADIOLOGY   (Italy)

ⁿ UNIVERSITY OF FLORENCE   (Italy)

^o UNIVERSITY OF PERUGIA   (Italy)

^p UNIVERSITY OF L'AQUILA   (Italy)

^q HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE RECEPTOR; PEGVISOMANT; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXON; FEMALE; GENE DELETION; GENE FREQUENCY; GENE LOCATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MOLECULAR PATHOLOGY; MONOTHERAPY; MULTICENTER STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, SOMATOTROPIN; SOMATOSTATIN;

EID: 84856769933     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1769     Document Type: Article

References (29)

1. Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M, Amselem S 2000 Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J Biol Chem 275:18664-18669
2. Urbanek M, Russell JE, Cooke NE, Liebhaber SA 1993 Functional characterization of the alternatively spliced, placental human growth hormone receptor. J Biol Chem 268:19025-19032 (Pubitemid 23273856)
3. Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougnères P 2004 A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 36:720-724 (Pubitemid 38886633)
4. Strawbridge RJ, Kärvestedt L, Li C, Efendic S, Ostenson CG, Gu HF, Brismar K 2007 GHR exon 3 polymorphism: association with type 2 diabetes mellitus and metabolic disorder. Growth Horm IGF Res 17:392-398 (Pubitemid 47324304)
5. Kenth G, Shao Z, Cole DE, Goodyer CG 2007 Relationship of the human growth hormone receptor exon 3 genotype with final adult height and bone mineral density. J Clin Endocrinol Metab 92:725-728
6. Jorge AA, Marchisotti FG, Montenegro LR, Carvalho LR, Mendonca BB, Arnhold IJ 2006 Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency. J Clin Endocrinol Metab 91:1076-1080 (Pubitemid 43357783)
7. Binder G, Baur F, Schweizer R, Ranke MB 2006 The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. J Clin Endocrinol Metab 91:659-664 (Pubitemid 43236940)
8. Pilotta A, Mella P, Filisetti M, Felappi B, Prandi E, Parrinello G, Notarangelo LD, Buzi F 2006 Common polymorphisms of the growth hormone (GH) receptor do not correlate with the growth response to exogenous recombinant human GH in GH deficient children. J Clin Endocrinol Metab 91:1178-1180 (Pubitemid 43357798)
9. Carrascosa A, Esteban C, Espadero R, Fernández-Cancio M, Andaluz P, Clemente M, Audí L, Wollmann H, Fryklund L, Parodi L; Spanish SGA Study Group 2006 The d3/fl growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients. J Clin Endocrinol Metab 91:3281-3286
10. Blum WF, Machinis K, Shavrikova EP, Keller A, Stobbe H, Pfaeffle RW, Amselem S 2006 The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor. J Clin Endocrinol Metab 91:4171-4174 (Pubitemid 44536901)
11. Carrascosa A, Audí L, Fernández-Cancio M, Esteban C, Andaluz P, Vilaró E, Clemente M, Yeste D, Albisu MA, Gussinyé M 2008 The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age. J Clin Endocrinol Metab 93:764-770 (Pubitemid 351398551)
12. de Graaff LC, Meyer S, Els C, Hokken-Koelega AC 2008 GH receptor d3 polymorphism in Dutch patients with MPHD and IGD born small for gestational age. Clin Endocrinol (Oxf) 68:930-934 (Pubitemid 351703952)
13. Räz B, Janner M, Petkovic V, Lochmatter D, Eblé A, Dattani MT, Hindmarsh PC, Flück CE, Mullis PE 2008 Influence of growth hormone receptor d3 and full-length isoforms on growth hormone response and final height in patients with severe growth hormone deficiency. J Clin Endocrinol Metab 93:974-980 (Pubitemid 351398582)
14. Schreiner F, Stutte S, Bartmann P, Gohlke B, Woelfle J 2007 Association of the growth hormone receptor d3-variant and catch-up growth of preterm infants with birth weight of less than 1500 grams. J Clin Endocrinol Metab 92:4489-4493 (Pubitemid 350074776)
15. Audí L, Esteban C, Carrascosa A, Espadero R, Pérez-Arroyo A, Arjona R, Clemente M, Wollmann H, Fryklund L, Parodi LA; Spanish SGA Study Group 2006 Exon 3-deleted/full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational age (SGA) children and adolescents (n = 247) and in adult control population (n = 289) show increased fl/fl in short SGA. J Clin Endocrinol Metab 91:5038-5043
16. van der Klaauw AA, van der Straaten T, Baak-Pablo R, Biermasz NR, Guchelaar HJ, Pereira AM, Smit JW, Romijn JA 2008 Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults. J Clin Endocrinol Metab 93:2828-2834 (Pubitemid 352008558)
17. Wassenaar MJ, Dekkers OM, Pereira AM, Wit JM, Smit JW, Biermasz NR, Romijn JA 2009 Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis. J Clin Endocrinol Metab 94:3721-3730
18. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A; Acromegaly Consensus Group 2009 Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517
19. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ 2002 Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646 (Pubitemid 35191626)
20. Bianchi A, Mazziotti G, Tilaro L, Cimino V, Veltri F, Gaetani E, Pecorini G, Pontecorvi A, Giustina A, De Marinis L 2009 Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly. Pituitary 12:196-199
21. Bernabeu I, Alvarez-Escolá C, Quinteiro C, Lucas T, Puig-Domingo M, Luque-Ramírez M, de Miguel-Novoa P, Fernandez-Rodriguez E, Halperin I, Loidi L, Casanueva FF, Marazuela M 2010 The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly. J Clin Endocrinol Metab 95:222-229
22. Giavoli C, Ferrante E, Profka E, Olgiati L, Bergamaschi S, Ronchi CL, Verrua E, Filopanti M, Passeri E, Montefusco L, Lania AG, Corbetta S, Arosio M, Ambrosi B, Spada A, Beck-Peccoz P 2010 Influence of the d3 GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy. Eur J Endocrinol 163:361-368
23. Montefusco L, Filopanti M, Ronchi CL, Olgiati L, La-Porta C, Losa M, Epaminonda P, Coletti F, Beck-Peccoz P, Spada A, Lania AG, Arosio M 2010 D3-growth hormone receptor in acromegaly: effects on metabolic phenotype. Clin Endocrinol (Oxf) 72:661-667
24. Kamenicky P, Dos Santos C, Espinosa C, Salenave S, Galland F, Le Bouc Y, Maison P, Bougnères P, Chanson P 2009 D3 GH receptor polymorphisms is not associated with IGF1 levels in untreated acromegaly. Eur J Endocrinol 161:231-235
25. Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L 2009 Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94:2015-2022
26. Mercado M, Gonzá lez B, Sandoval C, Esquenazi Y, Mier F, Vargas G, de los Monteros AL, Sosa E 2008 Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. J Clin Endocrinol Metab 93:3411-3415
27. Yu KD, Di GH, Fan L, Shao ZM 2009 Test of Hardy-Weinberg equilibrium in breast cancer case-control studies: an issue may influence the conclusions. Breast Cancer Res Treat 117:675-677
28. Schmid C, Krayenbuehl PA, Bernays RL, Zwimpfer C, Maly FE, Wiesli P 2007 Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene. Clin Chem 53:1484-1488 (Pubitemid 47206345)
29. Hodish I, Barkan A 2008 Long-term effects of pegvisomant in patients with acromegaly. Nat Clin Pract Endocrinol Metab 4:324-332 (Pubitemid 351733473)